Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
SNGX
SNGX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SNGX News
Soligenix Outlines Strategic Vision for 2026
4d ago
PRnewswire
Soligenix Provides Update on Clinical Trials and Strategic Options
4d ago
Newsfilter
Soligenix Publishes Positive Phase 2a Results for SGX945 in Behçet's Disease Treatment
Dec 18 2025
PRnewswire
Soligenix Expands Psoriasis Trial, Revealing Improved Results with New Gel
Dec 17 2025
Benzinga
Soligenix Reports Clinical Success of Optimized SGX302 Gel for Psoriasis Treatment
Dec 17 2025
PRnewswire
Soligenix Reaches Enrollment Target for Interim Analysis in Phase 3 Clinical Trial of HyBryte™ for Cutaneous T-Cell Lymphoma Treatment
Nov 19 2025
Newsfilter
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
Nov 07 2025
PRnewswire
Soligenix Reaches Key Safety Milestone in Phase 3 Clinical Trial of HyBryte™ for Treating Cutaneous T-Cell Lymphoma
Oct 07 2025
Newsfilter
Soligenix Expands European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Sep 30 2025
Newsfilter
Soligenix Announces Closing of $7.5 Million Public Offering
Sep 29 2025
PRnewswire
Soligenix Sets Price for $7.5 Million Public Offering
Sep 26 2025
Newsfilter
Soligenix Sets Public Offering Price at $1.35 per Share for $7.5 Million; Stock Rises in Pre-market Trading
Sep 26 2025
NASDAQ.COM
Soligenix Shares Decline Following $7.5M Public Offering Announcement to Raise Funds
Sep 26 2025
SeekingAlpha
Soligenix Appoints Former White House Economic Adviser Tomas J. Philipson, PhD, as Strategic Advisor
Sep 23 2025
Newsfilter
Soligenix Publishes Findings on Long-Term High-Temperature Stability of Protein Subunit Vaccines for Ebola and Similar Viruses
Sep 04 2025
Newsfilter
5 Healthcare Stocks Soaring This Week
Aug 21 2025
Benzinga
Show More News
